All the Drug Class Drugs
Selective Immunosuppressants. Vedolizumab 300 mg. VIAL (pwdr. for conc. for sol. for infus.): 1. Ulcerative colitis: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter. Ther. for pts. with ulcer. colit. should be discont. if no evidence of therapeutic benefit is observed by wk 10.
Pts. who exper. decr. in response may incr. in dosing freq. to 300 mg every 4 wks.
Pts. who have respond. to tmt. with 300 mg, corticost. may be reduced and/or discount. in accord. with standard of care. 2. Crohn’s disease: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter.
Pts. with Crohn’s dis., who have not shown a response may benefit from a dose at wk 10. Ther. should be cont. every 8 wks. from wk 14 in respond. pts. Therapy for pts. with Crohn’s dis. should be discont. if no eviden. of therap. benefit is observ. by wk 14. See lit.
Tmt. of adult pts. with moder.-sever. act. ulcer. colitis who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a TNFα antagonist.
Tmt. of adult pts. with moder.-sever. act Crohn’s dis. who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a ther. or a TNFα antagonist.
C/I: Hypersens. Act. severe infec. such as tuberculosis, sepsis, CMV, listeriosis, and opportunis. infec. such as PML.
Selective Immunosuppressants. Alemtuzumab 10 mg/ml. VIAL (conc. for sol. for infus.): 1 x 12 mg.
Recom. dose is 12 mg/d admin. by IV
infus. for 2 tmt. courses. Init. tmt.
course: 12 mg/d for 5 consec. days (60
mg total dose). 2nd tmt. course: 12
mg/d for 3 consec. days (36 mg total
dose) admin. 12 mths. after the init.
Adult pts. with RRMS with active dis.
defined by clinical or imaging features.
Selective Immunosuppressants. Abatacept 125 mg/ml, 250 mg. PRE-FILLED SYRINGE: 4 Syr (single dose)
125 mg SC inj. once wkly. W or w/o an
IV load. dose. Pts. transit. from IV ther.
to SC administ. 1st SC dose instead of
the next scheduled IV dose.
Reduct. signs and symp., inducing
major clinic. response, inhib. the
progress. of struct. damage, and
improve. phys. func. in adult pts. with
moderat. to severe. act. RA.
Used as monother.or concom. DMARDs
other than TNF antagonists.
VIAL (pwdr for conc. for infus.): 1x250mg. See lit.
As monotherapy for tmt. mod.-severe
active rheum. arthrit. in adults with
DMARDs other than TNF antagonists . A
reduct. in progress. joint damage and
improv. phys. funct. have been
demonstrat. In combinat. tmt. with abatacept and methotrexate. In
combinat.with methotrexate for tmt.
mod.-severe active polyarticul. juvenile
idiopathic arthrit. (JIA) in ped. pts 6 yrs of
age and older, with insuffic. response to
other DMARDs incl. at least one TNF
inhibitor. Has not been studied in child. <
C/I: Should not be administered
concomitantly with TNF antagonists. Is
not recommended for use
concomitantly with other biologic
rheumatoid arthritis (RA) therapy.
Selective Immunosuppressants. Apremilast 10, 20, 30 mg. F.C. TAB: Init. Pack: 4 x 10 mg, 4 x 20 mg, 19 x 30 mg; 56 x 30 mg.
Recommend. dose 30 mg x 2 /d, every 12 h. Init. titration require. See lit.
Tmt. of adult pts. with active psoriatic arthritis. For pts. with mod. to sev. plaque psoriasis who are candid. for photother. or syst. ther.